Holen Sie sich die Stockscreener-App
5.27
3.33%
0.17
Vorhandelsmarkt:
5.27
Schlusskurs vom Vortag:
$5.10
Offen:
$5.1
24-Stunden-Volumen:
1.81M
Relative Volume:
0.83
Marktkapitalisierung:
$289.58M
Einnahmen:
$3.64M
Nettoeinkommen (Verlust:
$-87.37M
KGV:
-1.2822
EPS:
-4.11
Netto-Cashflow:
$-86.46M
1W Leistung:
+7.77%
1M Leistung:
+6.90%
6M Leistung:
-4.53%
1J Leistung:
+54.09%
1-Tages-Spanne:
$4.86
$5.30
1-Wochen-Bereich:
$4.81
$5.57
52-Wochen-Spanne:
$2.10
$9.10
Verastem Inc Stock (VSTM) Company Profile
Firmenname
Verastem Inc
Sektor
Branche
Telefon
(781) 292-4200
Adresse
117 KENDRICK STREET, NEEDHAM, MA
Vergleichen Sie VSTM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
5.27 | 268.70M | 3.64M | -87.37M | -86.46M | -4.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Eingeleitet | Jefferies | Buy |
| 2025-03-24 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-31 | Bestätigt | BTIG Research | Buy |
| 2024-09-30 | Eingeleitet | Guggenheim | Buy |
| 2023-11-21 | Fortgesetzt | BTIG Research | Buy |
| 2023-09-27 | Eingeleitet | B. Riley Securities | Buy |
| 2023-06-15 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-07 | Fortgesetzt | Alliance Global Partners | Buy |
| 2022-04-29 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-04-14 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-03-09 | Eingeleitet | Truist | Buy |
| 2021-07-01 | Eingeleitet | Alliance Global Partners | Buy |
| 2021-05-24 | Hochstufung | BTIG Research | Neutral → Buy |
| 2019-06-20 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-05-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | Eingeleitet | BTIG Research | Buy |
| 2018-05-02 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-03-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-13 | Eingeleitet | Oppenheimer | Outperform |
| 2017-03-24 | Bestätigt | H.C. Wainwright | Buy |
| 2015-09-29 | Herabstufung | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | Herabstufung | Jefferies | Buy → Hold |
| 2015-09-29 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | Herabstufung | Mizuho | Buy → Neutral |
| 2015-09-28 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2015-09-09 | Eingeleitet | Raymond James | Strong Buy |
| 2015-05-12 | Bestätigt | UBS | Buy |
| 2015-04-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-01-23 | Bestätigt | ROTH Capital | Buy |
| 2014-07-08 | Fortgesetzt | Oppenheimer | Perform |
| 2014-02-11 | Eingeleitet | Mizuho | Buy |
Alle ansehen
Verastem Inc Aktie (VSTM) Neueste Nachrichten
Verastem Inc. Stock Analysis and ForecastMarket-beating returns - jammulinksnews.com
What analysts say about Verastem Inc. stockSkyrocketing profit margins - jammulinksnews.com
Is Verastem Inc. a good long term investmentConsistent triple-digit returns - jammulinksnews.com
(VSTM) Proactive Strategies - news.stocktradersdaily.com
What drives Verastem Inc. stock priceOutstanding stock performance - jammulinksnews.com
Verastem’s Promising KRAS G12D Inhibitor Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Verastem: The Market Is Ignoring The Progress (NASDAQ:VSTM) - Seeking Alpha
Why Verastem Inc. stock attracts strong analyst attentionDaily Trade Opportunity - beatles.ru
What makes Verastem Inc. stock price move sharplyEntry Level Low Risk Picks - Newser
How Verastem Inc. stock performs during market volatilityFast Moving Stock Alerts - Newser
Avutometinib-Defactinib: A New Standard in Precision Oncology? - AInvest
Verastem’s avutometinib combination shows 31% ORR in ovarian cancer trial - Yahoo Finance
Verastem Oncology's Breakthrough in LGSOC: A New Standard of Care with Substantial Upside Potential - AInvest
Verastem’s cancer drug shows 31% response rate in ovarian cancer trial By Investing.com - Investing.com Canada
Verastem stock rises after LGSOC treatment data published in medical journal - Investing.com
Verastem stock rises after LGSOC treatment data published in medical journal By Investing.com - Investing.com South Africa
Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology - Yahoo Finance
KRAS Inhibitors Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Target Population, Revenue, Statistics, MOA, ROA and Companies DelveInsight - Barchart.com
Verastem Oncology's Talent Incentives: Balancing Equity Dilution and Growth - AInvest
Verastem Oncology announces inducement grants under Nasdaq listing rule - MarketScreener
Verastem Oncology Awards 45,000 Share Options at $4.29 Each to Expand Cancer Drug Development Team - Stock Titan
Verastem’s Phase 3 Study on Avutometinib and Defactinib: A Potential Game-Changer for Ovarian Cancer Treatment - TipRanks
Verastem’s Promising Phase 3 Study on Recurrent Ovarian Cancer - TipRanks
How the (VSTM) price action is used to our Advantage - news.stocktradersdaily.com
Verastem’s Promising Phase 3 Study on Avutometinib and Defactinib in Ovarian Cancer - TipRanks
Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers - Seeking Alpha
Verastem (VSTM) Target Price Lowered by RBC Capital | VSTM Stock News - GuruFocus
RBC Capital Adjusts Target Price for Verastem (VSTM) to $12 | VS - GuruFocus
RBC Capital Adjusts Target Price for Verastem (VSTM) to $12 | VSTM Stock News - GuruFocus
Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors - BioSpace
Verastem Executives Sell Shares to Meet Tax Obligations - TradingView
Verastem CEO Paterson sells $1.8k in shares By Investing.com - Investing.com Canada
Verastem’s SWOT analysis: biotech stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Verastem’s SWOT analysis: biotech stock poised for growth amid challenges - Investing.com
(VSTM) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Verastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns Bullish - MSN
ASCO 2025: Verastem has positive cancer data but stock sags - BioWorld MedTech
Finanzdaten der Verastem Inc-Aktie (VSTM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):